Skip to content
← Full study record

NCT04223856 · MORE INFO

Limitations, agreements, and source contact

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer · Source last updated 2026-05-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
point Of Contact
email
medinfo@seagen.com
organization
Seagen Inc.
phone
(855) 473-2436
title
Chief Medical Officer
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
point Of Contact
email
medinfo@seagen.com
organization
Seagen Inc.
phone
(855) 473-2436
title
Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice